Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook
Apyx Medical reported Q3 2024 financial results with total revenue of $11.5 million, down 4% year-over-year. The company's Advanced Energy segment decreased 6% to $9.3 million, while OEM revenue increased 3% to $2.2 million. Despite overall decline, single-use handpiece revenue grew 9% overall and 15% in the U.S. The company secured $7.0 million through a registered direct offering and implemented cost-saving measures, including a 25% reduction in U.S. workforce expected to save $4.3 million annually. Updated 2024 guidance projects total revenue of $46.6-47.6 million, representing a 9-11% decrease from 2023, with net loss expected at approximately $25.0 million.
Apyx Medical ha riportato i risultati finanziari del terzo trimestre 2024, con un fatturato totale di 11,5 milioni di dollari, in calo del 4% rispetto all'anno precedente. Il segmento Advanced Energy dell'azienda è diminuito del 6% a 9,3 milioni di dollari, mentre il fatturato OEM è aumentato del 3% a 2,2 milioni di dollari. Nonostante il calo complessivo, il fatturato degli strumenti monouso è cresciuto del 9% nel complesso e del 15% negli Stati Uniti. L'azienda ha raccolto 7,0 milioni di dollari attraverso un'offerta diretta registrata e ha implementato misure di risparmio sui costi, tra cui una riduzione del 25% della forza lavoro negli Stati Uniti, che si prevede porterà a un risparmio annuale di 4,3 milioni di dollari. La guida aggiornata per il 2024 prevede un fatturato totale di 46,6-47,6 milioni di dollari, il che rappresenta una diminuzione del 9-11% rispetto al 2023, con una perdita netta prevista di circa 25,0 milioni di dollari.
Apyx Medical reportó resultados financieros del tercer trimestre de 2024, con ingresos totales de 11,5 millones de dólares, una disminución del 4% en comparación con el año anterior. El segmento Advanced Energy de la empresa cayó un 6% a 9,3 millones de dólares, mientras que los ingresos OEM incrementaron un 3% a 2,2 millones de dólares. A pesar de la caída general, los ingresos por piezas desechables crecieron un 9% en general y un 15% en EE. UU. La empresa aseguró 7,0 millones de dólares a través de una oferta directa registrada e implementó medidas de ahorro de costos, incluida una reducción del 25% en la fuerza laboral de EE. UU., lo que se espera que ahorre 4,3 millones de dólares anuales. La guía actualizada para 2024 prevé ingresos totales de 46,6-47,6 millones de dólares, lo que representa una disminución del 9-11% en comparación con 2023, con una pérdida neta esperada de aproximadamente 25,0 millones de dólares.
Apyx Medical는 2024년 3분기 재무 결과를 보고했으며, 총 수익은 1,150만 달러로 전년 대비 4% 감소했습니다. 회사의 고급 에너지 부문은 6% 감소하여 930만 달러에 이르렀고, OEM 수익은 3% 증가하여 220만 달러로 나타났습니다. 전반적인 감소에도 불구하고, 일회용 핸드피스 수익은 전체적으로 9%, 미국에서는 15% 증가했습니다. 회사는 등록된 직접 공모를 통해 700만 달러를 확보하였고, 미국 인력의 25% 감축을 포함한 비용 절감 조치를 시행하여 연간 430만 달러를 절감할 것으로 예상하고 있습니다. 2024년 업데이트된 가이드는 총 수익이 4,660만에서 4,760만 달러에 이를 것으로 예측되며, 이는 2023년 대비 9-11% 감소를 나타내고, 순손실은 약 2,500만 달러로 예상됩니다.
Apyx Medical a annoncé ses résultats financiers pour le troisième trimestre 2024, avec des revenus totaux de 11,5 millions de dollars, en baisse de 4% par rapport à l'année précédente. Le segment Énergie Avancée de l'entreprise a diminué de 6% à 9,3 millions de dollars, tandis que les revenus OEM ont augmenté de 3% pour atteindre 2,2 millions de dollars. Malgré le déclin général, les revenus des pièces à usage unique ont augmenté de 9% dans l'ensemble et de 15% aux États-Unis. L'entreprise a sécurisé 7,0 millions de dollars grâce à une offre directe enregistrée et a mis en œuvre des mesures d'économie de coûts, y compris une réduction de 25% de la main-d'œuvre aux États-Unis, qui devrait générer des économies annuelles de 4,3 millions de dollars. Les prévisions mises à jour pour 2024 projettent des revenus totaux de 46,6 à 47,6 millions de dollars, représentant une baisse de 9 à 11% par rapport à 2023, avec une perte nette prévue d'environ 25,0 millions de dollars.
Apyx Medical hat die Finanzzahlen für das dritte Quartal 2024 veröffentlicht, mit einem Gesamtumsatz von 11,5 Millionen Dollar, was einem Rückgang von 4% im Vergleich zum Vorjahr entspricht. Der Bereich der fortschrittlichen Energie des Unternehmens fiel um 6% auf 9,3 Millionen Dollar, während der OEM-Umsatz um 3% auf 2,2 Millionen Dollar anstieg. Trotz des allgemeinen Rückgangs wuchs der Umsatz mit Einweg-Handstücken insgesamt um 9% und um 15% in den USA. Das Unternehmen sicherte sich 7,0 Millionen Dollar durch ein registriertes Direktangebot und setzte Kostensenkungsmaßnahmen um, darunter eine Reduzierung von 25% der US-Belegschaft, die voraussichtlich jährliche Einsparungen von 4,3 Millionen Dollar bringen wird. Die aktualisierte Prognose für 2024 geht von einem Gesamtumsatz von 46,6-47,6 Millionen Dollar aus, was einem Rückgang von 9-11% im Vergleich zu 2023 entspricht, mit einer voraussichtlichen Nettoverlust von etwa 25,0 Millionen Dollar.
- Secured $7.0 million through registered direct offering
- Single-use handpiece revenue grew 9% overall and 15% in U.S.
- Cost savings restructuring expected to save $4.3 million annually
- OEM revenue increased 3% year-over-year to $2.2 million
- International revenue increased 11% year-over-year to $3.7 million
- Total revenue decreased 4% year-over-year to $11.5 million
- Advanced Energy revenue declined 6% to $9.3 million
- Gross profit margin decreased to 60.5% from 66.6%
- Net loss increased to $4.7 million
- Downward revision of 2024 revenue guidance to $46.6-47.6 million
- Expected net loss of $25.0 million for 2024, up from $18.7 million in 2023
Insights
The Q3 2024 results and revised guidance reveal significant challenges for Apyx Medical. Total revenue declined
The company's strategic moves include a
The amended credit agreement with Perceptive, while providing near-term flexibility, came at the cost of equity dilution and new operating expense constraints. The
The development of the Ayon body contouring system represents a strategic pivot toward market expansion. This all-in-one platform integrating multiple functions (Renuvion, ultrasound-assisted liposuction, power-assisted liposuction, infiltration, aspiration, electrocoagulation and fat transfer) could provide a competitive edge in the aesthetic surgical market.
However, the
- Strengthened balance sheet with a common stock registered direct offering with gross proceeds of approximately
$7.0 million ; and amended revenue covenants for the Company’s credit agreement with Perceptive - Announces cost savings restructuring program to better focus, optimize and streamline operations, including a nearly
25% reduction in U.S. workforce - Announces
9% overall growth in single-use handpiece revenue and15% growth in the U.S. - Management to host a conference call today at 8:00 a.m. ET
CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its third quarter ended September 30, 2024, updated its financial expectations for the full year ending December 31, 2024, and introduced its financial expectations for the full year ending December 31, 2025.
Recent Financial and Operating Highlights:
- Total revenue of
$11.5 million , a decrease of4% year-over-year, including:- Advanced Energy revenue of
$9.3 million , a decrease of6% year-over-year, and - OEM revenue of
$2.2 million , an increase of3% year-over-year.
- Advanced Energy revenue of
- Net loss attributable to stockholders of
$4.7 million , an increase of$0.1 million , or2% , year-over-year. - Adjusted EBITDA loss of
$2.4 million , a decrease of$0.6 million , or20% , year-over-year. - Closed a
$7.0 million registered direct offering with a healthcare-focused fund. - Amended the Company’s credit agreement with Perceptive Credit Holdings IV, LP (“Perceptive”) to significantly reduce the trailing twelve-month Advanced Energy revenue covenants. Additionally, a maximum operating expense covenant of
$40.0 million and$45.0 million in for 2025 and 2026, respectively was added. Associated with the amendment, Apyx issued 150,000 shares of common stock to Perceptive Advisors. - Implemented a cost saving restructuring program that included an organizational reduction in force to better focus, optimize and streamline operations. Under the organizational changes, the Company will reduce its U,S. workforce by nearly
25% . The annualized future cost savings from the reduction in force is estimated to be approximately$4.3 million . The Company will incur pre-tax charges of approximately$0.6 million in the fourth quarter of 2024, mostly represented as one-time severance expenditures and other employee termination benefits. Identified over$4.0 million of additional cost savings and anticipate operating expenses to be below$40 million in 2025. - Right sized the Company’s board of directors to five members down from eight.
“While our Advanced Energy sales decreased year-over-year, we were pleased with the continued resiliency of our disposable handpiece, which grew
Mr. Goodwin continued, “In addition, the Apyx team is in the final stages of developing the Ayon body contouring system, a new product that we believe will dominate the aesthetic surgical space. This system is an all-in-one platform that seamlessly integrates Renuvion, ultrasound-assisted liposuction, power-assisted liposuction, infiltration, aspiration, electrocoagulation and fat transfer into a single, streamlined device. We currently plan to submit a 510(k) for Ayon to the FDA no later than the end of the first quarter of 2025, and, pending approval, launch the system in the back half of 2025.”
In addition, as part of the cost restructuring, Todd Hornsby, Executive Vice President of Sales and Marketing, will be leaving the Company effective immediately.,” stated Mr. Goodwin. “I will be stepping into that role, in addition to my other duties. In order to free up my time, I am pleased to announce Shawn Roman has been promoted from his current position of Vice President Research and Development to Chief Operating Officer. Shawn has been with the Company since 2015 and is well qualified for his new role. ”
The following tables present revenue by reportable segment and geography:
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||
| September 30, | September 30, | |||||||||||||||||||||||||||||||
| (In thousands) | 2024 | 2023 | $ Change | % Change | 2024 | 2023 | $ Change | % Change | ||||||||||||||||||||||||
| Advanced Energy | $ | 9,288 | $ | 9,836 | $ | (548 | ) | (5.6 | )% | $ | 26,507 | $ | 31,248 | $ | (4,741 | ) | (15.2 | )% | ||||||||||||||
| OEM | 2,199 | 2,140 | 59 | 2.8 | % | 7,373 | 6,439 | 934 | 14.5 | % | ||||||||||||||||||||||
| Total | $ | 11,487 | $ | 11,976 | $ | (489 | ) | (4.1 | )% | $ | 33,880 | $ | 37,687 | $ | (3,807 | ) | (10.1 | )% | ||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||
| September 30, | September 30, | |||||||||||||||||||||||||||||||
| (In thousands) | 2024 | 2023 | $ Change | % Change | 2024 | 2023 | $ Change | % Change | ||||||||||||||||||||||||
| Domestic | $ | 7,793 | $ | 8,652 | $ | (859 | ) | (9.9 | )% | $ | 23,459 | $ | 27,660 | $ | (4,201 | ) | (15.2 | )% | ||||||||||||||
| International | 3,694 | 3,324 | 370 | 11.1 | % | 10,421 | 10,027 | 394 | 3.9 | % | ||||||||||||||||||||||
| Total | $ | 11,487 | $ | 11,976 | $ | (489 | ) | (4.1 | )% | $ | 33,880 | $ | 37,687 | $ | (3,807 | ) | (10.1 | )% | ||||||||||||||
Third Quarter 2024 Results:
Total revenue for the three months ended September 30, 2024, decreased to
Gross profit for the three months ended September 30, 2024, decreased to
Operating expenses decreased to
Other expense, net for the three months ended September 30, 2024 and 2023 was
Income tax expense (benefit) was
Net loss attributable to stockholders was
Adjusted EBITDA loss for the three months ended September 30, 2024 and 2023 was
Financial Guidance for Full Year 2024 and 2025:
The Company is updating its financial guidance for the year ending December 31, 2024 to:
- Total revenue is now expected to be in the range of
$46.6 million to$47.6 million , representing a decrease from 2023 of approximately11% to9% . The Company’s prior guidance range for total revenue was$50.6 million to$52.1 million .- Total revenue guidance assumes:
- Revenue from the Advanced Energy segment is now expected to be in the range of
$37.2 million to$38.2 million , representing a decrease from 2023 of approximately14% to12% . The Company’s prior guidance range for Advanced Energy revenue was$41.6 million to$43.1 million . - Revenue from the OEM segment is now expected to be approximately
$9.4 million , representing growth of approximately5% from 2023. The Company’s prior guidance for OEM revenue was approximately$9.0 million .
- Revenue from the Advanced Energy segment is now expected to be in the range of
- Total revenue guidance assumes:
- Net loss attributable to stockholders is now expected to be approximately
$25.0 million , compared to$18.7 million for the year ended December 31, 2023. The Company’s prior guidance range for net loss attributable to stockholders was$24.5 million to$23.5 million .
The Company is introducing revenue guidance for the year ending December 31, 2025:
- Total revenue in the range of
$47.6 million to$49.5 million , representing growth of approximately2% to6% year-over-year, compared to$46.6 million the low-end of the updated total revenue guidance for the year ended December 31, 2024.- Total revenue guidance assumes:
- Advanced Energy revenue is expected to be in the range of
$39.1 million to$41.0 million , representing growth of approximately5% to10% year-over-year, compared to approximately$37.2 million the low-end of the revenue guidance for Advanced Energy for the year ended December 31, 2024. - OEM revenue is expected to be approximately
$8.5 million , representing a decrease of approximately10% year-over-year, compared to the updated OEM revenue guidance of$9.4 million for the year ended December 31, 2024.
- Advanced Energy revenue is expected to be in the range of
- Total revenue guidance assumes:
- The Company also expects operating expenses of less than
$40 million for the year ended December 31, 2025.
Conference Call Details:
Management will host a conference call at 8:00 a.m. Eastern Time on November 8, 2024 to discuss the results of the third quarter, and to host a question and answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international callers) and provide access code 13749764. Participants should ask for the Apyx Medical Corporation call. A live webcast of the call will be accessible via the Investor Relations section of the Company’s website (click here) and accessible directly (click here).
An archive of the webcast will be accessible approximately one hour after the live event ends on the Investor Relations section of the Company’s website (click here).
Investor Relations Contact:
Jeremy Feffer, Managing Director LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
Cautionary Statement on Forward-Looking Statements:
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.
Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; the impact of the March 14, 2022 FDA Safety Communication on our business and operations; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
| APYX MEDICAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Sales | $ | 11,487 | $ | 11,976 | $ | 33,880 | $ | 37,687 | ||||||||
| Cost of sales | 4,533 | 3,998 | 13,484 | 12,857 | ||||||||||||
| Gross profit | 6,954 | 7,978 | 20,396 | 24,830 | ||||||||||||
| Other costs and expenses: | ||||||||||||||||
| Research and development | 1,142 | 1,409 | 3,963 | 4,037 | ||||||||||||
| Professional services | 1,648 | 1,831 | 5,318 | 5,165 | ||||||||||||
| Salaries and related costs | 3,508 | 4,534 | 12,886 | 14,329 | ||||||||||||
| Selling, general and administrative | 4,291 | 4,841 | 14,026 | 15,474 | ||||||||||||
| Total other costs and expenses | 10,589 | 12,615 | 36,193 | 39,005 | ||||||||||||
| Gain on sale-leaseback | — | — | — | 2,692 | ||||||||||||
| Loss from operations | (3,635 | ) | (4,637 | ) | (15,797 | ) | (11,483 | ) | ||||||||
| Interest income | 378 | 248 | 1,312 | 478 | ||||||||||||
| Interest expense | (1,431 | ) | (585 | ) | (4,254 | ) | (1,362 | ) | ||||||||
| Other income (expense), net | 24 | (19 | ) | 2 | 622 | |||||||||||
| Total other expense, net | (1,029 | ) | (356 | ) | (2,940 | ) | (262 | ) | ||||||||
| Loss before income taxes | (4,664 | ) | (4,993 | ) | (18,737 | ) | (11,745 | ) | ||||||||
| Income tax expense (benefit) | 60 | (318 | ) | 163 | (2,519 | ) | ||||||||||
| Net loss | (4,724 | ) | (4,675 | ) | (18,900 | ) | (9,226 | ) | ||||||||
| Net loss attributable to non-controlling interest | (21 | ) | (46 | ) | (65 | ) | (120 | ) | ||||||||
| Net loss attributable to stockholders | $ | (4,703 | ) | $ | (4,629 | ) | $ | (18,835 | ) | $ | (9,106 | ) | ||||
| Loss per share: | ||||||||||||||||
| Basic and diluted | $ | (0.14 | ) | $ | (0.13 | ) | $ | (0.54 | ) | $ | (0.26 | ) | ||||
| APYX MEDICAL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) | ||||||||
| September 30, 2024 | ||||||||
| (Unaudited) | December 31, 2023 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 28,013 | $ | 43,652 | ||||
| Trade accounts receivable, net of allowance of | 13,036 | 14,023 | ||||||
| Inventories, net of provision for obsolescence of | 9,000 | 9,923 | ||||||
| Prepaid expenses and other current assets | 2,109 | 2,764 | ||||||
| Total current assets | 52,158 | 70,362 | ||||||
| Property and equipment, net of accumulated depreciation and amortization of | 1,905 | 1,915 | ||||||
| Operating lease right-of-use assets | 4,820 | 5,162 | ||||||
| Finance lease right-of-use assets | 53 | 69 | ||||||
| Other assets | 1,785 | 1,732 | ||||||
| Total assets | $ | 60,721 | $ | 79,240 | ||||
| LIABILITIES AND EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,914 | $ | 2,712 | ||||
| Accrued expenses and other current liabilities | 7,291 | 9,661 | ||||||
| Current portion of operating lease liabilities | 330 | 347 | ||||||
| Current portion of finance lease liabilities | 20 | 20 | ||||||
| Total current liabilities | 9,555 | 12,740 | ||||||
| Long-term debt, net of debt discounts and issuance costs | 33,853 | 33,185 | ||||||
| Long-term operating lease liabilities | 4,606 | 4,896 | ||||||
| Long-term finance lease liabilities | 38 | 53 | ||||||
| Long-term contract liabilities | 1,271 | 1,246 | ||||||
| Other liabilities | 201 | 198 | ||||||
| Total liabilities | 49,524 | 52,318 | ||||||
| EQUITY | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 35 | 35 | ||||||
| Additional paid-in capital | 84,289 | 81,114 | ||||||
| Accumulated deficit | (73,283 | ) | (54,448 | ) | ||||
| Total stockholders’ equity | 11,041 | 26,701 | ||||||
| Non-controlling interest | 156 | 221 | ||||||
| Total equity | 11,197 | 26,922 | ||||||
| Total liabilities and equity | $ | 60,721 | $ | 79,240 | ||||
APYX MEDICAL CORPORATION
RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA
(Unaudited)
Use of Non-GAAP Financial Measure
We present the following non-GAAP measure because we believe such measure is a useful indicator of our operating performance. Our management uses this non-GAAP measure principally as a measure of our operating performance and believes that this measure is useful to investors because it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We also believe that this measure is useful to our management and investors as a measure of comparative operating performance from period to period. The non-GAAP financial measure presented in this release should not be considered as a substitute for, or preferable to, the measures of financial performance prepared in accordance with GAAP.
The Company has presented the following non-GAAP financial measure in this press release: adjusted EBITDA. The Company defines adjusted EBITDA as its reported net income (loss) attributable to stockholders (GAAP) plus income tax expense (benefit), interest, depreciation and amortization, stock-based compensation expense and other significant non-recurring items.
| Three Months Ended | Nine Months Ended | |||||||||||||||
| (In thousands) | September 30, | September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net loss attributable to stockholders | $ | (4,703 | ) | $ | (4,629 | ) | $ | (18,835 | ) | $ | (9,106 | ) | ||||
| Interest income | (378 | ) | (248 | ) | (1,312 | ) | (478 | ) | ||||||||
| Interest expense | 1,431 | 585 | 4,254 | 1,362 | ||||||||||||
| Income tax expense (benefit) | 60 | (318 | ) | 163 | (2,519 | ) | ||||||||||
| Depreciation and amortization | 144 | 186 | 457 | 540 | ||||||||||||
| Stock based compensation | 997 | 1,351 | 3,175 | 4,200 | ||||||||||||
| Gain on sale-leaseback | — | — | — | (2,692 | ) | |||||||||||
| Adjusted EBITDA | $ | (2,449 | ) | $ | (3,073 | ) | $ | (12,098 | ) | $ | (8,693 | ) | ||||
FAQ
What was Apyx Medical's Q3 2024 revenue?
How much did Apyx Medical raise in their recent offering?
What are Apyx Medical's cost-saving measures for 2024?
What is Apyx Medical's revenue guidance for 2024?
